Second-line chemotherapy versus supportive cancertreatment in advanced gastric cancer: A meta-analysis

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2850-2854

  Kim, H S ^a   Kim, H J ^b   Kim, S Y ^c   Kim, T Y ^d,d   Lee, K W ^e   Baek, S K ^c   Ryu, M H ^f   Nam, B H ^g   Zang, D Y ^a  

^a Hallym University Medical Center   (China)

^b Korea University College of Medicine   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Seoul National University Hospital   (South Korea)

^e Seoul National University Bundang Hospital   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g National Cancer Center   (South Korea)

Author keywords

Advanced gastric cancer; Best supportive care; Meta analysis; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; IRINOTECAN;

ADVANCED CANCER; ARTICLE; BEST SUPPORTIVE CARE; CANCER CHEMOTHERAPY; DEATH; DRUG EFFICACY; DRUG RESPONSE; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SALVAGE THERAPY; STOMACH CANCER; THERAPY; THERAPY EFFECT;

ADVANCED GASTRIC CANCER; BEST SUPPORTIVE CARE; META-ANALYSIS; SECOND-LINE CHEMOTHERAPY;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CLINICAL TRIALS, PHASE III AS TOPIC; FLUOROURACIL; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TAXOIDS;

EID: 84887116455     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt351     Document Type: Article

References (12)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Jung KW, Won YJ, Kong HJ et al. Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010. Cancer Res Treat 2013; 45: 1-14.
3. Wagner AD, Unverzagt S, Grothe W et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2010; CD004064.
4. Thuss-Patience PC, Kretzschmar A, Bichev D et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47: 2306-2314.
5. Kang JH, Lee SI, Lim do H et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 2012; 30: 1513-1518.
6. Cook N, Marshall A, Blazeby JM et al. COUGAR-02: a randomized phase III study of docetaxel versus active symptom control in patients with relapsed esophagogastric adenocarcinoma. J Clin Oncol 2013; 31 (suppl): abstract 4023.
7. Ueda S, Hironaka S, Yasui H et al. Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. J Clin Oncol 2012; 30 (suppl): abstract 4002.
8. Roy AC, Park SR, Cunningham D et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol 2013; 24: 1567-1573.
9. Catalano V, Graziano F, Santini D et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99: 1402-1407.
10. Ji SH, Lim do H, Yi SY et al. A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. BMC Cancer 2009; 9: 110-115.
11. Kanagavel D, Pokataev IA, Fedyanin MY et al. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy. Ann Oncol 2010; 21: 1779-1785.
12. Hasegawa H, Fujitani K, Nakazuru S et al. Optimal indications for second-line chemotherapy in advanced gastric cancer. Anticancer Drugs 2012; 23: 465-470.